Flucytosine shortage — GR supply status & alternatives

Flucytosine

—

In supply · Australia

Ancotil

In supply · 🇦🇺 Australia · short in🇬🇷 GR

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Flucytosine
Brand names	Ancotil
Therapeutic category	Auto-created by Agence nationale de sécurité du médicament — Disponibilité scraper

Marketing-authorisation holders	MAJOR PHARMACEUTICALS

Registrations on file	2

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 2 resolved events

◷

1–21 months

Historical pattern from resolved shortage records — not a prediction of this event.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

6 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Moderate concentration risk✓ 1 WHO-prequalified

Solara Active Pharma Sciences LimitedCalyx Chemicals And Pharmaceuticals LTDNantong Jinghua Pharmaceutical CO LTDMatrix Pharmacorp Private LTDMaithri Laboratories Private LTDSolara Active Pharma Sciences LTD

Manufacturing countries: India, China · Source: FDA List of Drug Master Files

FDA-approved products 🇺🇸 Drugs@FDA

Approved applications

Generic (ANDA)

Brand (NDA/BLA)

July 2017

Latest approval

Shortage status by regulator official notices

🇬🇷

EOF · 1d ago

Medium

🇫🇷

France

ANSM · 1d ago

Resolved

Recalls official enforcement reports

🇺🇸

Flucytosine Active Pharmaceutical Ingredient Packaged In Var

Attix Pharmaceuticals · Nov 2014

Class IIdetails ↗

Verified timeline regulator events

🇬🇷 4 May 2026

medium reported

🇬🇷 2 Feb 2026

Shortage resolved

🇫🇷 18 Sept 2024

Shortage resolved

Sources official regulators

🇬🇷

EOF

verified 1d ago

verify ↗

🇫🇷

ANSM

verified 1d ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders2 registrations · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
Flucytosine	250mg/1	capsule	🇺🇸 US	MAJOR PHARMACEUTICALS	Active
Flucytosine	500mg/1	capsule	🇺🇸 US	MAJOR PHARMACEUTICALS	Active

Mederti Drug Report

Generated 6 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.